REVIEW article
Front. Pharmacol.
Sec. Experimental Pharmacology and Drug Discovery
Volume 16 - 2025 | doi: 10.3389/fphar.2025.1642927
This article is part of the Research TopicTranslational Potential of Novel Biomarkers and Molecular Targets in Lifestyle DisordersView all 6 articles
Potential Biomarkers in Early Detection of Gastric Cancer
Provisionally accepted
Supreet Kaur1
Ankush Kumar1Rohit Bhatia1Diksha Choudhary1
Rajwinder Kaur1*
Balakumar Chandrasekaran2*
Wael Abu Dayyih3- 1Chitkara University, Rajpura, India
- 2Philadelphia University, Amman, Jordan
- 3Mutah University, Mu'tah, Jordan
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Abstract The annual burden of gastric cancer (GC) is increasing, highlighting a major threat to global public health. The important contributing factor to this increased fatality of disease is the late stage at which GC is usually detected. Recent advancements in genomic and molecular studies have spearheaded the discovery of novel biomarkers for early-stage GC. Enabled by metabolomic, genetic, epigenetic and proteomic signatures, these biomarkers have the potential to change the diagnostic outlook for GC. Such biomarkers would allow the detection of disease even in its infancy stage, thereby improving the quality of life of those inflicted with this disease and also lowering the mortality rate. This review aims to provide a thorough overview of the novel biomarkers in GCs. Further, this review addresses the mechanism by which these biomarkers are linked to detection of GC and their possible utilisation in clinical settings. This review comprises several such novel biomarkers such as Heat Shock Protein Family A6 (HSPA6), Annexin A11 (ANXA11), Cell Division Cycle 42 (CDC42), Fibroblast Activation Protein-alpha (FAP), Hepcidin Antimicrobial Peptide (HAMP), Solute Carrier Family 25 member 4 (SLC25A4), Serpin Peptidase Inhibitor Clade H Member 1 (SERPINH1), Cystatin B, Deleted in Malignant Brain Tumours 1 (DMBT1), Nuclear Paraspeckle Assembly Transcript 1 (NEAT1), N6-methyladenosine-related lncRNAs, Circular RNAs and Proteinase 3 (PRTN3). Thus, the aim of this review is to gather and incorporate the current state of knowledge on this particular topic in order to point out the need for persistent research and innovation in the field of identification of GC biomarkers. This will enable the opportunity for new and more effective strategies for combating GC, which will further reduce its global burden and improve survival of patients. This review comprises several such novel biomarkers that have made early diagnosis of GC possible to decrease its mortality.
Keywords: biomarkers, Cancer, gastric cancer, signalling pathways, proliferation
Received: 07 Jun 2025; Accepted: 22 Sep 2025.
Copyright: © 2025 Kaur, Kumar, Bhatia, Choudhary, Kaur, Chandrasekaran and Abu Dayyih. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Rajwinder Kaur, rajwinder.kaur@chitkara.edu.in
Balakumar Chandrasekaran, dhillbalu@gmail.com
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.